title: An open-label study of the safety and efficacy of sertaconazole nitrate in the treatment of seborrheic dermatitis.
abstract: OBJECTIVE
  To demonstrate the efficacy and evaluate the safety of sertaconazole nitrate cream 2% in the treatment of seborrheic dermatitis (SD).
  
  
  METHODS
  Single-center, open-label study.
  
  
  METHODS
  One academic medical center.
  
  
  METHODS
  Twenty adult male and female subjects aged 22 to 85 years (average, 56 years) with mild-to-severe seborrheic dermatitis of the face.
  
  
  METHODS
  The primary efficacy evaluation was the proportion of subjects with a score of 0 or 1 at the end of treatment (week 4) on the Investigator's Static Global Assessment scale. Secondary end points included percent change from baseline to week 4 in sum individual scores of erythema, scaling, induration, and pruritus at a preselected target lesion. Other end points included change in scores on Subject's Global Assessment scale and the Dermatology Life Quality Index.
  
  
  RESULTS
  Success on the primary end point was achieved by 10 of 17 evaluable subjects (58.8%). Improvements in Investigator's Static Global Assessment score from baseline were statistically significant at each week. Significant improvements were also demonstrated in erythema, scaling, induration, and pruritus at week 4 compared to baseline. Improvement in Subject's Global Assessment scores compared to baseline were significant only at week 1 (P=0.031). Change in total mean SD Dermatology Life Quality Index scores from baseline to week 4 was 0.34 (± 0.62, P=0.039).
  
  
  CONCLUSIONS
  The results of this preliminary study support the efficacy and safety of sertaconazole nitrate cream, 2%, for the treatment of seborrheic dermatitis.
authors.affiliation: University of Alabama, Birmingham, Alabama, USA. BEElewski@aol.com
authors.forename: Boni E
authors.initials: BE
authors.lastname: Elewski
authors.forename: Wendy C
authors.initials: WC
authors.lastname: Cantrell
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D012628:Dermatitis, Seborrheic / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D004890:Erythema / Q000188:drug therapy; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D008290:Malassezia / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D013876:Thiophenes / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D007093:Imidazoles; D013876:Thiophenes; C061131:sertaconazole